These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23131875)

  • 1. Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder.
    Miller S; Ittasakul P; Wang PW; Hill SJ; Childers ME; Rasgon N; Ketter TA
    J Clin Psychopharmacol; 2012 Dec; 32(6):814-9. PubMed ID: 23131875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients.
    Wang PW; Hill SJ; Childers ME; Chandler RA; Rasgon NL; Ketter TA
    J Psychiatr Res; 2011 Aug; 45(8):1128-32. PubMed ID: 21371718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive aripiprazole in treatment-resistant bipolar depression.
    Ketter TA; Wang PW; Chandler RA; Culver JL; Alarcon AM
    Ann Clin Psychiatry; 2006; 18(3):169-72. PubMed ID: 16923655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of lamotrigine in bipolar disorder in a clinical setting.
    Ketter TA; Brooks JO; Hoblyn JC; Champion LM; Nam JY; Culver JL; Marsh WK; Bonner JC
    J Psychiatr Res; 2008 Nov; 43(1):13-23. PubMed ID: 18423667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression.
    Ahn YM; Nam JY; Culver JL; Marsh WK; Bonner JC; Ketter TA
    Ann Clin Psychiatry; 2011 Feb; 23(1):17-24. PubMed ID: 21318192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study.
    Wang PW; Yang YS; Chandler RA; Nowakowska C; Alarcon AM; Culver J; Ketter TA
    J Psychiatr Res; 2008 May; 42(6):451-7. PubMed ID: 17628595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
    Citrome L; Reist C; Palmer L; Montejano LB; Lenhart G; Cuffel B; Harnett J; Sanders KN
    Schizophr Res; 2009 Dec; 115(2-3):115-20. PubMed ID: 19864113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
    Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.
    Sacchetti E; Galluzzo A; Valsecchi P
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):163-79. PubMed ID: 22115400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer-Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder.
    Miller S; Do D; Gershon A; Wang PW; Hooshmand F; Chang LS; Ketter TA
    J Clin Psychopharmacol; 2018 Jun; 38(3):207-211. PubMed ID: 29620693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.